Episode 54
Biotech Hangout
00:00
Smit Cup Biotech Stocks Are Down or Not Where They Could Be
There are still so many promising companies with good data and or Phase 2 or Phase 3 and could be blockbuster drugs over the next five to seven years. We're supposed to understand that big pharma has as much cash as ever before and yet we see more Smit Cup companies with data than ever before. So there seems to be a dichotomy and valuation's argument as low as they have been in years.
Transcript
Play full episode
